<DOC>
	<DOCNO>NCT01951911</DOCNO>
	<brief_summary>To see whether addition low-dose ketamine subcutaneous morphine infusion improve analgesia patient neuropathic cancer pain .</brief_summary>
	<brief_title>Effectiveness Ketamine Malignant Neuropathic Pain Relief</brief_title>
	<detailed_description>Patients cancer pain judge neuropathic component receive pain treatment subcutaneous infusion morphine include randomize , double blind , placebo-controlled , crossover study . All patient recruit hospital ward ( Haukeland University Hospital , Bergen ) . In case patient withdrawal dropout , new patient recruit total number patient complete study 20 . Data patient complete study solely use provide information adverse effect . The basic treatment subcutaneous morphine infusion supplement separate subcutaneous infusion ketamine 1 mg/kg/ 24 hour NaCl 9 mg/ml ( placebo ) . After 48 hour ( phase 1 ) `` wash-out '' period minimum 10 hour minimize carryover effect treatment replace alternative treatment 48 hour ( phase 2 ) standard crossover design . The treatment duration base ketamine 's short plasma half-life le 2 hour initial equilibration . Pain intensity ( use NRS ) record rest movement x 4 daily . Rescue medication form morphine subcutaneous bolus may give patient require . There '' lockout '' time 1 hour mean rescue dose morphine repeat every 60 minute necessary , provide patient awake respiratory rate 8 per minute.Randomization perform Haukeland University Hospital Pharmacy . The study drug/ placebo also prepare hospital pharmacy accord standard instruction .</detailed_description>
	<mesh_term>Pain , Intractable</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Age 1870 year . Inpatient . Cancer pain judge neuropathic component . Clinically normal renal hepatic function . Able cooperate understand information . Worst pain rest movement 5 ( NRS 010 ) . Pain currently treat continuous subcutaneous morphine infusion . The daily morphine dose 48mg per 24 hour 30 % increase daily dose provide sufficient pain relief . Not treat ketamine last 48 hour prior inclusion . Reduced renal hepatic function . Suspicion morphine toxicity ( sedation , hallucination , myoclonus , increase pain ) . Increased intracranial pressure ( suspicion cerebral metastasis ) cerebral metastasis . Unable cooperate/ understand information . Worst pain rest movement le 5 NRS . Current treatment opioids morphine . The patient undergo radiotherapy pain area , receive radiotherapy pain area within last four week . Changes use analgesic ( paracetamol , NSAIDS ) , adjuvant drug ( antidepressant , antiepileptic , corticosteroid , muscle relaxant ) dosages less 2 day prior inclusion study period . Pregnant lactating woman . Any situation increase blood pressure would constitute hazard . Acute intermittent porphyria . Psychiatric illness , epilepsy , alcoholism , glaucoma . Hypersensitivity drug ingredient . Current treatment ketamine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pain Management</keyword>
	<keyword>Ketamine</keyword>
	<keyword>Palliative care</keyword>
</DOC>